73673 Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB82
DOI: 10.1016/j.jaad.2026.04.338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von April Armstrong und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Armstrong, A., Pérez-Chada, L., Lebwohl, M., Balak, D. M., Lewitt, G. M., Warren, R. B., Langley, R. G., Thaçi, D., Han, G., Herr, H., & Blauvelt, A. (2026). 73673 Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 95(1), AB82. https://doi.org/10.1016/j.jaad.2026.04.338
Vancouver
Armstrong A, Pérez-Chada L, Lebwohl M, Balak DM, Lewitt GM, Warren RB, et al. 73673 Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology. 2026;95(1):AB82. doi:10.1016/j.jaad.2026.04.338
BibTeX
@article{Armstrong2026,
author = {Armstrong, April and Pérez-Chada, Lourdes and Lebwohl, Mark and Balak, Deepak M.W. and Lewitt, George M. and Warren, Richard B. and Langley, Richard G. and Thaçi, Diamant and Han, George and Herr, Heather and Blauvelt, Andrew},
title = {73673 Bimekizumab on-treatment remission as defined by the National Psoriasis Foundation: 1-year results versus ustekinumab and secukinumab in patients with moderate to severe plaque psoriasis},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB82},
doi = {10.1016/j.jaad.2026.04.338}
}
EUVIMED